{
    "clinical_study": {
        "@rank": "104279", 
        "arm_group": {
            "arm_group_label": "BI 655064 subcutaneous", 
            "arm_group_type": "Experimental", 
            "description": "Escalating single dose as subcutaneous injection"
        }, 
        "brief_summary": {
            "textblock": "BI 655064 will be administered subcutaneously once weekly in patients with immune\n      thrombocytopenic purpura (ITP) for up to 12 weeks."
        }, 
        "brief_title": "Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Purpura, Thrombocytopenic, Idiopathic", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Male and female chronic immune ITP patients\n\n        Exclusion criteria:\n\n        Any treatment of ITP excluded except for a stable dose of corticosteroids (up to 20 mg)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009761", 
            "org_study_id": "1293.7"
        }, 
        "intervention": {
            "arm_group_label": "BI 655064 subcutaneous", 
            "description": "subcutaneous injection", 
            "intervention_name": "BI 655064", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "1293.7.10001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary efficacy endpoint is the number of patients with response in platelet count", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with drug-related adverse events", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "The secondary endpoint is the number of patients reaching the cut off point for ITP, which is defined as platelet count greater than or equal to 100,000 at any visit", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}